60
Participants
Start Date
December 11, 2023
Primary Completion Date
June 1, 2027
Study Completion Date
June 30, 2027
Etripamil NS
"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
RECRUITING
Hospital Infantil Universitario La Paz, Madrid
NOT_YET_RECRUITING
Universitätsmedizin Göttingen, Klinik für Pädiatrische Kardiologie, Intensivmedizin und Neonatologie, Göttingen
NOT_YET_RECRUITING
Le Bonheur Children's Hospital, Memphis
NOT_YET_RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
NOT_YET_RECRUITING
Advocate Children's Hospital, Oak Lawn
NOT_YET_RECRUITING
Baylor College of Medicine, Houston
RECRUITING
Phoenix Children's Hospital, Phoenix
RECRUITING
Oregon Health and Science University, Portland
NOT_YET_RECRUITING
The University of British Columbia, Vancouver
NOT_YET_RECRUITING
Hospital Sant Joan de Déu, Barcelona
Lead Sponsor
Milestone Pharmaceuticals Inc.
OTHER